Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1035620140020010064
Allergy Asthma & Respiratory Disease
2014 Volume.2 No. 1 p.64 ~ p.69
Effectiveness of double-dose oseltamivir for pediatric patients with severe 2009 pandemic influenza A H1N1
Cho Hyun-Seok

Yang Jeong-Hee
Lee Joon-Ho
Ahn Sung-Yeon
Lee Hyeon-Soo
Kim Ja-Kyoung
Min Se-Ra
Abstract
Purpose: We aimed to evaluate the use and safety of double dose oseltamivir for patients manifesting severe respiratory symptoms or showing no improvement of clinical symptoms after 72 hours¡¯ treatment with the usual oseltamivir dosage.

Methods: We analyzed the clinical features of 2009 influenza A H1N1 inpatients who had been admitted to a university hospital¡¯s Department of Pediatrics between August 2009 and January 2010. The Influenza A H1N1 diagnoses were confirmed by real-time reverse transcriptase polymerase chain reaction.

Results: The study participants numbered 157 (mean age, 5.0 years; male-to-female ratio, 1.1:1). Among them, twenty (mean age, 5.2 years) were administered double dose oseltamivir. This double dose group showed higher peak body temperatures and more abnormal radiologic results than the other, usual-dose group. The mean time duration between high fever and afebrile status after initiation of double-dose oseltamivir administration was 2.1 days, whereas that within the usual-dose group was 1.7 days. There were no adverse effects in the patients treated with double-dose oseltamivir.

Conclusion: Double-dose oseltamivir was well tolerated in patients with severe 2009 influenza A H1N1 infection.
KEYWORD
Influenza A virus, H1N1 subtype, Pediatrics, Severity of illness index, Oseltamivir
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed